HRL enters the final quarter of 2026 with the stock pressing against multi-year lows, short sellers gradually adding pressure, and the Street maintaining a cautious but not outright bearish stance after a punishing August earnings print.
The most striking feature of the past month is the sharp step-up in short interest that began in mid-September. Shares short jumped from roughly 17.3 million to above 21 million between September 9 and September 11, a move of more than 20% in two sessions, and have held at those elevated levels since. Short interest now represents 3.8% of the free float, up 9.4% over the past month. That is not an extreme level in absolute terms, but the speed of the build is notable. Borrow conditions remain undemanding: the cost to borrow is 0.46%, and availability is exceptionally loose at roughly 1,100%, meaning there are more than eleven shares available to lend for every one already borrowed. Nothing in the lending market suggests squeeze risk, and the borrow pool offers plenty of capacity for further short-selling if sentiment continues to deteriorate.
Options positioning has edged toward caution without reaching alarm levels. The put/call ratio is 0.58, modestly above its 20-day average of 0.51 and about 0.75 standard deviations above the mean. That is a mild lean toward protection, not a panicked hedging rush. The 52-week high on the PCR is 0.67, touched on September 21, so the current reading is below peak defensiveness. The ORTEX short score has crept higher through the second half of September, reaching 41.4, though the 34th-percentile short-score rank within its sector means HRL is not yet registering as an extreme short-conviction name relative to packaged-food peers.
The Street is uniformly neutral on HRL and has been for some time. The most recent analyst action of note came from BNP Paribas on August 28, when the firm trimmed its target to $26 from $27 while keeping a Neutral rating, following a sharp earnings-day drop of more than 9%. JP Morgan had raised its target to $26 from $25 in mid-August, also at Neutral, before the print undid the logic of that move. The consensus mean target is $26.13 against a current price of $19.85, implying roughly 32% upside on paper, but the Street's inability to find a positive catalyst worth upgrading is the cleaner read. The EV/EBITDA multiple has drifted down 0.08 turns over the past 30 days to 9.4x, and the price-to-book has compressed 0.14 turns over the same period to 1.40x. The forward earnings yield has risen mechanically as the price has fallen, now approaching 7.7%. The bull case rests on Hormel's portfolio pruning toward higher-margin brands and a recovery in the Foodservice segment, while bears point to commodity exposure, private-label competition, and the ongoing question of whether new retail leadership can stabilise margins.
Ownership is dominated by a single structural anchor. The Hormel Foundation holds 46.6% of shares, a stake that has not changed, effectively locking out any near-term control dispute. Among institutional holders, the standard index managers (State Street, Vanguard, BlackRock) hold positions in the 3.6% to 4.7% range with modest recent additions. Dimensional Fund Advisors added more than 2.5 million shares as of August 31, the largest single institutional build in the visible data, which is consistent with a value-screen-driven accumulation at depressed prices rather than a conviction call on the catalyst. The activist register carries no 13D filers. The only notable insider transaction in the past 90 days was a discretionary open-market sale by director Gary Bhojwani in early July, 20,200 shares at $24.51, totalling just under $500,000 and not conducted under a 10b5-1 plan. With the stock now trading nearly $4.70 below that sale price, the timing looks unfortunate in hindsight, but a single director sale carries limited informational weight.
The earnings history adds important context. The most recent print on August 27 sent HRL down more than 9% on the day and an additional 8.6% over the following five sessions, a particularly severe double-leg reaction that explains much of the stock's 8% decline over the past month. The next earnings event is scheduled for December 3. With 64 days to the print and the stock already deeply depressed, the question for the coming weeks is whether the monthly short-interest build has found a floor or whether sellers continue to press ahead of what the market clearly treats as a high-event-risk reporting date.
See the live data behind this article on ORTEX.
Open HRL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
